BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Jyothy Laboratories Ltd.’s Q1 FY23 revenue was in line with our estimate. Elevated commodity costs kept gross margin under pressure. The adverse impact was reflected in Ebitda margin, which stood at 10.2% (our estimate: 12.5%).
Revenue compound annual growth rate has been tepid at 5.5% over the preceding five years ended FY22. Revenue growth is the key for a company with sales of only ~Rs 22 billion.
The likelihood of a consistent 15% sales growth (essential for any re-rating) continues to appear difficult, despite Jyothy Labs’ efforts to ramp up its total and direct reach.
With margin likely to remain under pressure due to elevated material cost, its earnings growth prospects remain challenging.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.